Log In
BCIQ
Print this Print this
 

peretinoin (Ruchiko) (K-333, NIK-333)

  Manage Alerts
Collapse Summary General Information
Company Kowa Co. Ltd.
DescriptionOral acyclic retinoid with a vitamin A-like structure
Molecular Target Retinoic acid receptor (RAR) ; Retinoid X receptor (RXR)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationLiver cancer
Indication DetailsPrevent recurrence after curative treatment of HCV-related hepatocellular carcinoma (HCC); Prevent recurrence of hepatocellular carcinoma (HCC) in patients with HCV; Treat hepatocellular cancer (HCC)
Regulatory Designation EU - Orphan Drug (Treat hepatocellular cancer (HCC))
PartnerChugai Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/14/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today